A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension
The pharmacokinetic (PK) parameters of lisinopril were obtained in 46 children aged 6 months to 15 years. A lisinopril suspension (0.15 mg/kg per day) was administered to patients <6 years of age; the remaining children received lisinopril tablets, the daily dose being adjusted according to body weight, i.e., 2.5 mg if <25 kg, 5 mg if 25–45 kg, and 10 mg if >45 kg. Blood was drawn predose and on eight occasions postdose in children aged 4–15 years, and on five occasions in those aged <4 years. PK data are reported for the 46 children in terms of age groups: Group I (n = 9), aged 6–23 months; Group II (n = 8), aged 2–5 years; Group III (n = 12), aged 6–11 years; Group IV (n = 17), aged 12–15 years. The dose of lisinopril ranged from 3.07 mg/m2 per day in Group I to 4.78 mg/m2 per day in Group IV. Cmax of lisinopril, which occurred 5–6 h postdose, varied from 22 ng/ml in Groups I and II to 44 ng/ml in Groups III and IV; AUC0–24 h ranged from 301–311 ng·h/ml in Groups I and II to 550–570 ng·h/ml in Groups III and IV. No serious adverse events related to lisinopril were reported.